drugset
drugset / Trial / NCT01401868

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

NCT01401868 ↗

Phase 1 Completed 18 enrolled MEI Pharma, Inc. SCRI Development Innovations, LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the tolerability of ME-143, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.

Timeline

Start
2011-09
Primary completion
2012-09
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ME-143 Unknown 2.5 mg/kg Intravenous
Subject ME-143 Unknown 5 mg/kg Intravenous
Subject ME-143 Unknown 7.5 mg/kg Intravenous
Subject ME-143 Unknown 10 mg/kg Intravenous
Subject ME-143 Unknown 15 mg/kg Intravenous
Subject ME-143 Unknown 20 mg/kg Intravenous

Indications

cancer